Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The human immunodeficiency virus

W D Hardy1

  • 1Center for Infectious Diseases, Bronx-Lebanon Hospital Center, New York, USA.

The Medical Clinics of North America
|November 1, 1996
PubMed
Summary
This summary is machine-generated.

Optimism grows for HIV-1 treatment. Lowering viral load (HIV-1 plasma RNA) with combination antiretroviral therapy, including RT and PR inhibitors, delays AIDS and prolongs survival.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Carotid artery thickness is associated with chronic use of highly active antiretroviral therapy in patients infected with human immunodeficiency virus: A 3.0 Tesla magnetic resonance imaging study.

HIV medicine·2015
Same author

Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients.

HIV medicine·2011
Same author

Evaluation of an indirect enzyme-linked immunosorbent assay for the detection of feline lentivirus-reactive antibodies in wild felids, employing a puma lentivirus-derived synthetic peptide antigen.

The Onderstepoort journal of veterinary research·2003
Same author

Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.

Antiviral therapy·2000
Same author

Designing salvage antiretroviral regimens. Some basic guidelines and use of resistance testing.

Postgraduate medicine·2000
Same author

Treatment of mucocutaneous herpes simplex virus infections unresponsive to acyclovir with topical foscarnet cream in AIDS patients: a phase I/II study.

Journal of acquired immune deficiency syndromes (1999)·1999
Same journal

Care Transitions Continue to Evolve.

The Medical clinics of North America·2026
Same journal

Navigating the Gaps: A Comprehensive Overview of Care Transitions Across the Continuum.

The Medical clinics of North America·2026
Same journal

Care Transitions and Value-Based Payment Models in the United States.

The Medical clinics of North America·2026
Same journal

Technology and Innovation in Care Transitions: Imagining the Future of Postdischarge Care.

The Medical clinics of North America·2026
Same journal

Primary Care, Specialists, and Hospitals: Bridging the Gaps in Communication and Coordination.

The Medical clinics of North America·2026
Same journal

Social Determinants of Health: Unique Considerations in Transitions of Care.

The Medical clinics of North America·2026
See all related articles

Area of Science:

  • Virology
  • Immunology
  • Infectious Diseases

Background:

  • A new understanding of Human Immunodeficiency Virus type 1 (HIV-1) virology, biology, and therapy is emerging.
  • HIV-1 plasma RNA levels are critical determinants of disease progression and survival.
  • Long-term survivors (nonprogressors) exhibit significantly lower HIV-1 replication and robust immune responses.

Purpose of the Study:

  • To summarize recent advances in HIV-1 research.
  • To highlight the importance of viral load in disease progression.
  • To discuss the impact of antiretroviral therapy on HIV-1 management.

Main Methods:

  • Analysis of HIV-1 plasma RNA levels as a measure of viremia.
  • Study of immune responses in long-term HIV-1 survivors.

Related Experiment Videos

  • Evaluation of combination antiretroviral therapies, including RT and PR inhibitors.

    • Main Results:

    • Reduced viremia correlates with delayed onset of Acquired Immunodeficiency Syndrome (AIDS) and prolonged survival.
    • Combination therapies can achieve undetectable viral loads and delay drug resistance.
    • HIV-1 subgroups show distinct geographical distributions, influencing transmission routes.

    Conclusions:

    • Controlling HIV-1 viremia is key to managing the disease.
    • Effective antiretroviral strategies can significantly improve patient outcomes.
    • Understanding HIV-1 diversity is crucial for targeted interventions.